NDC-12 Readiness
Ensure NDC-12 readiness across your organization
Preparing for the 12-Digit National Drug Code Format
The pharmaceutical industry is preparing for a significant regulatory shift as the National Drug Code expands from a 10-digit format to a standardized 12-digit NDC format. This NDC-12 transition affects far more than labeling. It impacts enterprise systems, master data, regulatory submissions, and supply chain operations.
Organizations that understand and begin NDC-12 readiness planning early will reduce disruption, protect data integrity, and avoid costly remediation across systems and partners.
Understanding the NDC-12 Transition
The transition to a 12 digit National Drug Code (NDC) format will affect far more than product labeling. Because NDCs are embedded across regulatory, commercial, and supply chain systems, all pharma organizations need to evaluate and understand how the change may impact their data, technology, downstream partners and operations.
-
What Is the 12 Digit NDC Format?
The 12-digit National Drug Code (NDC) format standardizes product identification across the United States, replacing the historical 10-digit NDC configurations. The FDA NDC update introduces a uniform structure designed to improve consistency, eliminate code shortages, and enhance data clarity across healthcare stakeholders.
However, moving from 10-digit to 12-digit NDC is not simply a formatting change. NDCs are embedded across ERP systems, master data platforms, serialization systems, pricing workflows, analytics environments, and downstream integrations.
Understanding where NDC data lives inside your organization is the first step toward a successful NDC conversion.
-
How will the transition to NDC-12 impact my organization?
The operational impact of NDC-12 extends across multiple domains:
Enterprise Systems: ERP, MDM, and labeling platforms must support 12-digit NDC logic.
Supply Chain & Serialization: Barcode updates, transaction processing, and partner coordination require alignment.
Regulatory & Quality Processes: SOPs, submission workflows, and compliance documentation must reflect the updated format.
Data Governance: Master data structures, reporting systems, and data warehouses must be assessed for downstream impact.
Without cross-functional coordination, the NDC-12 transition can introduce data inconsistencies, integration failures, and operational risk.
-
How will the transition affect my company’s systems and data?
The move from a 10-digit to a 12-digit National Drug Code will affect any system that stores, processes, or exchanges NDC data. This typically includes ERP systems, labeling platforms, master data management environments, serialization systems, regulatory submission tools, and analytics platforms. Companies will need to review database field lengths, integration logic, and reporting structures to ensure they can properly handle the standardized 12-digit format without introducing data inconsistencies.
-
How will the NDC-12 change impact our supply chain and external partners?
The NDC format is widely used across the pharmaceutical supply chain, including distributors, pharmacies, healthcare providers, and payers. As companies move to the 12-digit format, coordination with external partners will be essential to ensure systems, data exchanges, and transactional workflows remain aligned. Misalignment across trading partners can lead to ordering errors, billing discrepancies, or delays in product distribution if not carefully planned.
NDC-12 Readiness and Transition Planning Services
NNIT Services:
An NDC-12 Impact Assessment provides a structured evaluation of how National Drug Code data is used across your organization. The assessment identifies where NDCs reside within enterprise systems such as ERP platforms, regulatory submission tools, labeling systems, serialization solutions, and master data environments. It also examines how NDC data flows through operational processes including manufacturing, packaging, product registration, supply chain transactions, and reporting. By mapping these dependencies, organizations gain a clear understanding of where the transition from a 10-digit to a 12-digit NDC format may introduce operational or data risks and where remediation planning is required.
An NDC Readiness Assessment evaluates whether your organization’s systems, processes, and data structures are prepared to support the standardized 12-digit NDC format. The assessment includes a gap analysis across key environments such as ERP systems, labeling platforms, serialization solutions, regulatory systems, and reporting tools. Each system is reviewed to determine whether it can store, process, and transmit the expanded NDC format without modification. The result is a clear view of where updates, configuration changes, or coordination with vendors and partners may be required to ensure compatibility.
Transition Roadmap Development focuses on creating a phased execution plan to guide organizations through the NDC-12 transition. The roadmap aligns regulatory timelines with system updates, operational process changes, and coordination with external partners. It outlines the sequence of activities required to move from impact assessment to implementation, including system remediation, data updates, and validation testing. By establishing milestones and cross-functional ownership across regulatory, IT, supply chain, and quality teams, organizations can manage the transition in a coordinated and controlled manner.
NDC-12 Consulting and Advisory Services provide strategic guidance to help pharmaceutical organizations navigate the complexity of converting to the 12-digit NDC format. Our advisory approach focuses on aligning regulatory expectations with enterprise systems, operational processes, and data governance practices. We work with cross-functional stakeholders to establish governance structures, clarify ownership, and coordinate transition planning across the organization. This structured approach helps companies mitigate risk, maintain operational continuity, and prepare their systems and data for the future NDC standard.
The NDC-12 Cross-Industry Pilot
Cencora and NNIT collaborated to execute Phase 0 of the NDC-12 Industry Pilot. This foundational phase convened a select cross-industry group of stakeholders to assess how the transition to NDC-12 may impact manufacturers, wholesalers, and dispensers across the pharmaceutical supply chain.
Phase 1 of the NDC-12 Industry Pilot Program moves beyond Phase 0 - Assessment to now design, plan and simulate operational and interoperability processes to prepare for the Transition period where NDC-10, NDC-11, and NDC-12 formats coexist. Over a focused 3–4-month engagement, manufacturers, wholesalers, pharmacies, and industry organizations will examine how NDC functions as a critical identifier across pricing, contracting, transaction processing, reconciliation, compliance, and regulatory reporting.
Turn Regulatory Change into Strategic Advantage
The NDC-12 transition presents an opportunity to modernize master data practices, improve system interoperability, and strengthen supply chain resilience.
Organizations that approach NDC-12 strategically will not only achieve compliance, they will emerge with stronger data foundations and more agile operations.
